Immune Pharmaceuticals   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: New York NY United States (2010)
Status: Acquired by United General Ltd (2021)

Organization Overview

First Clinical Trial
2015
NCT01671956
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 4 Trials (2)

Key: Immune Pharmaceuticals (0) Acquired (2)

aldesleukin (proleukin) (4 trials)

histamine dihydrochloride (4 trials)

Drugs in Phase 2 Trials (5)

Key: Immune Pharmaceuticals (1) Acquired (4)

amitriptyline (elavil) (2 trials)

azacitidine (vidaza) (1 trial)

Bertilimumab (2 trials)

gabapentin (neurontin) (1 trial)

ketamine (ketalar) (2 trials)

Drugs in Phase 1 Trials (1)

Key: Immune Pharmaceuticals (0) Acquired (1)

crinobulin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Pemphigoid, Bullous (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 8